About Us

Management Team

Dr. Nancy Tawil 

Chief Scientific Officer

Ph.D in Biomedical Engineering and Phage Expert



Mark Engel

CEO

Mr. Engel has been founding and building life sciences companies  since 1990, including NPO Pharmaceuticals (successful exit); Excel PharmaStudies (successful exit); Tiger Medical Group (successful exit); and Haoyisheng (IPO ready). Mr. Engel also has a family fund investing in life science  organizations.

Sandy Li

Quality Manager

M.S. in Chemistry. Experienced in GMP

drug production



Bryan Li

EVP Medical

China Medical University graduate, majored in Medicine, certified by American ECFMG, and specialized in Dermatology. Trained and worked at the Dermatology Departments of China Medical University and Guangdong Medical University. Dr. Li was a visiting scholar at the Dermatology Department of Asian University in South Korea and a post-doc research fellow at the Dermatology Department of Boston University, with several publications in peer-reviewed Journals. Mr. Li has nearly 30 years experience in medical and clinical operations at Fortune 500 multinationals.

R&D Pipeline

We are focused on topical bacterial infection since the size of the market is so large and there are virtually no totally effective and affordable solutions. Over time, we will look to in-license other later stage biological dermatological treatments.

Overview

Phagelux is a Cayman platform company that utilizes phages and novel delivery systems to create First in Class treatments for large unmet or under met skin conditions. Phagelux Targets are effectively preventing and treating AMR resistant topical infections. Phagelux subsidiary Lysigen utilizes lysins to create first or best-in-class antibacterials with a focus on skin diseases. Phagelux has an R&D center in Montreal, Canada focused on bacteriophage products. Lysigen is located in Wuhan China and focuses on lysin products.

Phagelux has significant IP and unique knowhow. In total, 28 patents have been filed in China, US, Europe, and other key markets, and 8 patents have been issued. These include patents of preparation method and method of use. In addition, Phagelux has unique platform knowhow in phage delivery and Lysigen has a fast high throughput lysin development system.

Phagelux has two products ready to start clinical trials.


Technical Support: 赛泊斯 | Admin Login